ChemPartner PharmaTech Co Ltd (300149) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of ChemPartner PharmaTech Co Ltd stock ¥2.90, price ¥8.55, that is 66.1% below the price, quality 68 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range ¥3.79 – ¥20.55 · fair‑value band ¥2.74 – ¥3.22 · the ¥8.55 price screens above the ¥2.90 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.
Follow ChemPartner PharmaTech Co in your weekly email
Every Wednesday you see whether ChemPartner PharmaTech Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ChemPartner PharmaTech Co.,Ltd. engages in the microecological nutrition and healthcare businesses worldwide. The company operates in two segments, Microecological Nutrition and Medical Business; and Pharmaceutical Research and Development Service and Production Outsourcing Business.
Show moreShow less
It offers prebiotic products and the provision of microecological medical services.
The company provides comprehensive chemical drug research and development and biological drug services for large and medium-sized pharmaceutical companies, biotechnology companies, and scientific research institutions.
The company was formerly known as Quantum Hi-Tech (China) Biological Co., Ltd. and changed its name to ChemPartner PharmaTech Co.,Ltd. in September 2020. ChemPartner PharmaTech Co.,Ltd. was founded in 2000 and is headquartered in Guangzhou, China.
Stock analysis
ChemPartner PharmaTech Co Ltd (300149) currently trades at ¥8.55, while our model-based Fair Value estimate is ¥2.90, 66% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of ¥4.90 per share, and 0 of the 25 models we run sit above the ¥8.55 price.
Bear case: the Multiples group reads lowest at ¥0.5800, and 25 of the 25 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥2.74 (bear) to ¥3.22 (bull), the price of ¥8.55 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
ChemPartner PharmaTech Co Ltd reported revenue of 1.1B CNY in FY2025 versus 1.7B CNY in FY2021, a compound −9.5%/yr. Reported net income was 13.4M CNY in FY2025.
Key figures
Market cap 4.3B CNY (≈ $639M) Small · P/S ratio 3.49 · EPS (TTM) ¥−0.0800 · Dividend yield 0.1% · Net margin −3.7% · Return on equity −3.3% · Return on assets (EBIT) −0.2% (5-year average) · Operating margin 0.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −66%, 300149 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥0.0200 to ¥7.66). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear¥2.74Fair Value ¥2.90Bull¥3.22
Price ¥8.55 · Downside -66.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−37.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−38.0%
Dividend (yield on the price)0.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 3%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+21.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +19.4% a year for the price.
Compare ChemPartner PharmaTech Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside−66.1% · Below median
Profitability
Return on assets0.7% · Above median
Net margin (12 months)−3.7% · Below median
Operating margin (12 months)0.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)8.5% · Above median
Dividend yield (12 months)0.1% · Bottom 25%
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B3.34× · Pricier than median
P/S (12 months)3.66× · Cheaper than median
Price / free cash flow (fiscal year)33.3× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)43· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)99· sector 97
DIVIDEND (yield)1· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "ChemPartner PharmaTech Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300149
Frequently asked questions
Is ChemPartner PharmaTech Co Ltd (300149) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥2.90 versus a price of ¥8.55, about 66% lower (overvalued).
What is the fair value of 300149?
Our model-based fair value for ChemPartner PharmaTech Co Ltd is ¥2.90 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥8.55.
What is the quality score of 300149?
ChemPartner PharmaTech Co Ltd has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ChemPartner PharmaTech Co Ltd (300149)?
Our model-based price target is the fair value of ¥2.90 (as of Nov 7, 2026) from 26 valuation models. Cautious scenario ¥2.74, optimistic scenario ¥3.22. It is a calculation from audited fundamentals, not an analyst target.
What is the ChemPartner PharmaTech Co Ltd stock forecast for 2026?
Our models put fair value at ¥2.90, about 66% lower versus a price of ¥8.55 (overvalued). Cautious scenario ¥2.74, optimistic scenario ¥3.22. The calculation is refreshed regularly with new filings.
What is the revenue of ChemPartner PharmaTech Co Ltd (300149)?
ChemPartner PharmaTech Co Ltd reported trailing-twelve-month revenue of about 1.2B CNY (latest available figure, as of Nov 7, 2026).
Does ChemPartner PharmaTech Co Ltd pay a dividend?
ChemPartner PharmaTech Co Ltd currently shows a dividend yield of 0.07% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of ChemPartner PharmaTech Co Ltd (300149)?
ChemPartner PharmaTech Co Ltd has a dividend yield of 0.1%.
What growth is priced into ChemPartner PharmaTech Co Ltd (300149)?
For today's price to be fair in a discounted-cash-flow model, ChemPartner PharmaTech Co Ltd would have to grow free cash flow by +21.4 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -5.2 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 300149 use?
Our models discount ChemPartner PharmaTech Co Ltd at 11.2 %: a base by market capitalisation (small), damped by beta 0.75, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ChemPartner PharmaTech Co Ltd that is +21.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has ChemPartner PharmaTech Co Ltd (300149) delivered so far?
Over the past 5 years revenue at ChemPartner PharmaTech Co Ltd grew -5.2 % a year. The price currently implies free-cash-flow growth of +21.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ChemPartner PharmaTech Co Ltd (300149) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into ChemPartner PharmaTech Co Ltd (+21.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ChemPartner PharmaTech Co Ltd (300149)?
The free-cash-flow yield on the price is 3.01 %: that much free cash flow ChemPartner PharmaTech Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ChemPartner PharmaTech Co Ltd (300149)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ChemPartner PharmaTech Co Ltd it is ¥2.90 per share (as of Nov 7, 2026), against a price of ¥8.55. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is ChemPartner PharmaTech Co Ltd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 300149 trades above its calculated fair value: price ¥8.55, fair value ¥2.90, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300149?
No. The price is what the market pays today (¥8.55); the fair value is what the company's own numbers justify (¥2.90). For ChemPartner PharmaTech Co Ltd the two are ¥5.65 per share apart. That gap is exactly why we show both numbers side by side.
How much is ChemPartner PharmaTech Co Ltd worth?
The market values ChemPartner PharmaTech Co Ltd at about 4.3B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥8.55; our models calculate a fair value of ¥2.90 per share.
What do the bullish and bearish scenarios say about 300149?
Our models span a range for ChemPartner PharmaTech Co Ltd: cautious scenario ¥2.74, base ¥2.90, optimistic ¥3.22 per share (as of Nov 7, 2026, price ¥8.55). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ChemPartner PharmaTech Co Ltd (300149)?
Balance-sheet figures for ChemPartner PharmaTech Co Ltd (as of Nov 7, 2026): return on equity −3.3%, debt of 0.02 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is 300149 from its 52-week high?
ChemPartner PharmaTech Co Ltd trades at ¥8.55, about 33% below its 52-week high of ¥12.74 and 13% above the low of ¥7.55 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥2.90 is for.
Which stocks are comparable to ChemPartner PharmaTech Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ChemPartner PharmaTech Co Ltd stock attractive at the current price?
The data as of Nov 7, 2026: price ¥8.55, calculated fair value ¥2.90 (−66%), Quality Score 68/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300149 calculated?
We run ChemPartner PharmaTech Co Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥2.90 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. ChemPartner PharmaTech Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ChemPartner PharmaTech Co Ltd (300149)?
The closing price on Nov 6, 2026 was ¥8.55. Our model-based fair value is ¥2.90, about 66% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ChemPartner PharmaTech Co Ltd right now?
The price sits above even our optimistic bull case (¥3.22). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of ChemPartner PharmaTech Co Ltd
How large is the market capitalisation of ChemPartner PharmaTech Co Ltd (300149)?
The market capitalisation of ChemPartner PharmaTech Co Ltd is 4.3B CNY (≈ $639M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ChemPartner PharmaTech Co Ltd (300149)?
The price-to-sales ratio of ChemPartner PharmaTech Co Ltd is 3.49 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ChemPartner PharmaTech Co Ltd (300149)?
Earnings per share at ChemPartner PharmaTech Co Ltd are ¥−0.0800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of ChemPartner PharmaTech Co Ltd (300149)?
The dividend yield of ChemPartner PharmaTech Co Ltd is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of ChemPartner PharmaTech Co Ltd (300149)?
The net margin of ChemPartner PharmaTech Co Ltd is −3.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ChemPartner PharmaTech Co Ltd (300149)?
The return on equity (ROE) of ChemPartner PharmaTech Co Ltd is −3.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ChemPartner PharmaTech Co Ltd (300149)?
On an EBIT basis the return on assets of ChemPartner PharmaTech Co Ltd is −0.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ChemPartner PharmaTech Co Ltd (300149)?
The operating margin of ChemPartner PharmaTech Co Ltd is 0.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ChemPartner PharmaTech Co Ltd (300149)?
Revenue at ChemPartner PharmaTech Co Ltd is growing +8.5% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does ChemPartner PharmaTech Co Ltd (300149) carry?
The net debt of ChemPartner PharmaTech Co Ltd is 613M CNY (fiscal year 2021, ≈ 4.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch ChemPartner PharmaTech Co Ltd in the live analysis
One click puts ChemPartner PharmaTech Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026